Literature DB >> 9119652

Serum tumour markers in renal failure.

N Arik1, B Adam, T Akpolat, K Haşil, S Tabak.   

Abstract

In order to assess the clinical value of six tumour markers in pre-dialysis patients with chronic renal failure as well as in patients on regular haemodialysis, we studied these markers in 35 predialysis patients, 35 patients on chronic haemodialysis and 35 healthy controls. Serum squamous cell antigen (SCC), CA 19.9, and CA 125 levels were found to be elevated in the uraemic groups as compared to the normal controls. Carcinoembryonic antigen (CEA), alpha foetoprotein (AFP), and prostate-specific antigen (PSA) levels were within normal limits in all groups.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9119652     DOI： 10.1007/bf02550974

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  17 in total

1.  Tumor markers in patients undergoing hemodialysis or kidney transplantation.

Authors:  N Zeferos; G E Digenis; M Christophoraki; I Alexopoulos; A Kostakis; H Gyftaki; S Moulopoulos
Journal:  Nephron       Date:  1991       Impact factor: 2.847

2.  Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.

Authors:  E Odagiri; K Jibiki; M Takeda; H Sugimura; C Iwachika; Y Abe; K Kihara; Y Kihara; M Itou; T Nomura
Journal:  Am J Nephrol       Date:  1991       Impact factor: 3.754

3.  Malignancy in end-stage renal disease.

Authors:  R F Slifkin; J Goldberg; M S Neff; A Baez; N Mattoo; S Gupta
Journal:  Trans Am Soc Artif Intern Organs       Date:  1977

4.  Cancer in patients receiving long-term dialysis treatment.

Authors:  A F Kantor; R N Hoover; L J Kinlen; M R McMullan; J F Fraumenti
Journal:  Am J Epidemiol       Date:  1987-09       Impact factor: 4.897

5.  Tumor markers in chronic renal failure and hemodialysis patients.

Authors:  A Cases; X Filella; R Molina; A M Ballesta; J Lopez-Pedret; L Revert
Journal:  Nephron       Date:  1991       Impact factor: 2.847

6.  Tumor markers in patients with chronic renal failure.

Authors:  X Filella; A Cases; R Molina; J Jo; J L Bedini; L Revert; A M Ballesta
Journal:  Int J Biol Markers       Date:  1990 Apr-Jun       Impact factor: 2.659

7.  Serum CA 19-9 and CA 50 antigens in hemodialysis patients.

Authors:  D Docci; E Pistocchi; F Turci; L Baldrati; S Urbini; S Scaioli
Journal:  Clin Nephrol       Date:  1987-04       Impact factor: 0.975

8.  Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients.

Authors:  H Inamoto; R Ozaki; T Matsuzaki; M Wakui; T Saruta; A Osawa
Journal:  Nephron       Date:  1991       Impact factor: 2.847

9.  High incidence of neoplasia in uremic patients receiving long-term dialysis. Cancer and long-term dialysis.

Authors:  A Lindner; V T Farewell; D J Sherrard
Journal:  Nephron       Date:  1981       Impact factor: 2.847

10.  Tumor markers in uremia: carcinoembryonic antigen, neuron-specific enolase, carbohydrate antigen CA-50 and alpha-fetoprotein.

Authors:  N G DeSanto; S Veneroso; G Capodicasa; A Crisci; C Giordano
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754
View more
  9 in total

Review 1.  [Diagnostics and treatment of prostate cancer after kidney transplantation].

Authors:  A Wicht; A Hamza; H Loertzer; M Dietl; H Heynemann; P Fornara
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

2.  Prognostic significance of maternal urinary carbohydrate antigen 19-9 for antenatal diagnosis of posterior urethral valve associated with fetal hydronephrosis.

Authors:  Abdol-Mohammad Kajbafzadeh; Shabnam Sabetkish; Nastaran Sabetkish
Journal:  Int Urol Nephrol       Date:  2019-04-06       Impact factor: 2.370

3.  Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.

Authors:  Khawla Al Musalhi; Manal Al Kindi; Faiza Al Aisary; Fatma Ramadhan; Thuraya Al Rawahi; Khalsa Al Hatali; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2016-09

4.  Do hydronephrosis and extracorporeal shock wave lithotripsy affect carbohydrate antigens?

Authors:  Turgay Akgül; Bariş Nuhoğlu; Ali Ayyildiz; Uğur Balci; Sema Nur Ayyildiz; Cankon Germiyanoğlu
Journal:  Int Urol Nephrol       Date:  2007-03-03       Impact factor: 2.370

5.  Effect of renal function and hemodialysis on the serum tumor markers in patients with chronic kidney disease.

Authors:  Xiaofang Yu; Xialian Xu; Zhibin Ye
Journal:  Front Med China       Date:  2007-07

6.  How to define a cut-off value of tumour markers in haemodialysis patients?

Authors:  Lucile Mercadal; Sylvie Cormont; Sophie Tezenas-du-Montcel; Sabria Hacini; Marcia Venditto; Gilbert Deray
Journal:  NDT Plus       Date:  2009-04

Review 7.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

8.  Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy.

Authors:  Jianzhong Chen; Feng Tao; Bin Zhang; Qingguang Chen; Yan Qiu; Qian Luo; Yanna Gen; Jiali Meng; Jue Zhang; Hao Lu
Journal:  Int J Endocrinol       Date:  2017-07-04       Impact factor: 3.257

9.  Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.

Authors:  Gustav Mikkelsen; Arne Åsberg; Maria E Hultström; Knut Aasarød; Gunhild G Hov
Journal:  Int J Biol Markers       Date:  2017-10-31       Impact factor: 2.659
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.